Clinical trials: Staphylococcus Aureus Septicemia
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT00622882
- Testing
- infectious disease specialist consultation
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
Having bacteria in the blood can be very dangerous. This is called bacteraemia (or bacteremia) or bloodstream infection. It can lead to problems across the whole body, which is what happens in sepsis.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Sepsis Bacterial, Bloodstream Infection
- Trial name
- PET-SAB (NCT05361135)
- Testing
- PET/CT
- Volunteers
- 820 people
- Sponsor
- University College, London
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Sepsis, Sepsis Mrsa
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).
- Conditions
- Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy
- Trial name
- REVAMP (NCT05975671)
- Testing
- Multifaceted de-implementation strategy to reduce vancomycin overuse
- Where
- 4 sites in United States
- Volunteers
- 52,500 people
- Sponsor
- Children's Hospital of Philadelphia
Staphylococcus Aureus, Bacteremia
Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy
Staphylococcus aureus, the most virulent of the many staphylococcal species, has been recognized as one of the most important and lethal human bacterial pathogens.
- Trial name
- NCT01352936
- Where
- Taiwan
- Volunteers
- 190 people
- Sponsor
- Taipei Medical University WanFang Hospital
Methicillin Susceptible Staphylococcus Aureus Septicemia
Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin.
- Trial name
- SAFO (NCT03959345)
- Testing
- Combination therapy group, Standard therapy group
- Where
- 17 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Miquel Pujol
Blood Stream Infections, Endocarditis
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
1. Drug resistance of G+ cocci is a severe healthcare problem. According to the Ministry of Health National Antimicrobial Resistant Investigation Net (mohnarin) surveillance report, the isolation rate of MRSA is some 60% in…
- Conditions
- Blood Stream Infections, Endocarditis, MRSA
- Trial name
- NCT02443064
- Testing
- Vancomycin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang University
Staphylococcus Aureus
Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection
S. aureus bloodstream infection (SAB) is a severe disease associated with a 30% case-fatality rate at 12 weeks. Severity of this disease is related to the high prevalence of staphylococcal Deep Foci of Infection (SA-DFI), which…
- Trial name
- TEPSTAR (NCT03419221)
- Testing
- PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions, Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
- Where
- France
- Volunteers
- 291 people
- Sponsor
- University Hospital, Montpellier
Bacteremia
Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA
In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.
- Trial name
- NCT01640886
- Where
- 3 sites in United States
- Volunteers
- 764 people
- Sponsor
- MicroPhage, Inc.
Methicillin-resistant Staphylococcus Aureus, Sepsis
Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project
Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Sepsis, Critical Illness
- Trial name
- NCT02945241
- Testing
- Vancomycin, Cystatin C dosing algorithm, Creatine clearance dosing algorithm
- Volunteers
- 399 people
- Sponsor
- Mayo Clinic
Staphylococcus Aureus Infection
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
Increasing resistance to antibiotic agents has been recognized as a major health problem worldwide that will even aggravate due to the lack of new antimicrobial agents within the next decade [1].
- Trial name
- SABATO (NCT01792804)
- Testing
- Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid
- Where
- 40 sites in France, Germany and 3 more
- Volunteers
- 215 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Bacterial Infections
An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections
In July 2020, a bundle (Appendix C) was implemented at Methodist Dallas Medical Center where all patients with SAB were reviewed by the antimicrobial stewardship pharmacist (Monday - Friday from 0700 to 1500), a note outlining…
- Trial name
- NCT06211829
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Methodist Health System
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
- Conditions
- Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection
- Trial name
- DAPTO-SNAP (NCT06637332)
- Testing
- Daptomycin for Injection, Vancomycin (IV)
- Where
- 20 sites in Australia, Canada and 1 more
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Staphylococcus Aureus
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
Primary Objective: Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S.
- Trial name
- NCT00507247
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Staphylococcus Aureus Bacteremia
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral…
- Trial name
- EVOS (NCT06336824)
- Testing
- Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid, IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
- Where
- 12 sites in Malaysia
- Volunteers
- 290 people
- Sponsor
- Clinical Research Centre, Malaysia
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- AstraZeneca